Heron Therapeutics $HRTX, in its recent regulatory filing, reported that three executives will be departing as part of the company�s realignment strategy following the FDA approval of SUSTOL (granisetron). The executive who will be departing are: Neil Clendeninn, PhD, SVP, Chief Medical Officer; Paul Marshall, SVP, Technical operation (both resigned on September 30) and Brian Drazba, VP, Finance and CFO will resign effective March 31st, 2017.